BA BA - Skye Bioscience, President, Chairman
| SKYE Stock | USD 2.70 0.16 5.59% |
Insider
BA BA is President, Chairman of Skye Bioscience, Common
| Age | 43 |
| Address | 11250 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 410 0266 |
| Web | https://skyebioscience.com |
Skye Bioscience, Management Efficiency
The company has return on total asset (ROA) of (0.3039) % which means that it has lost $0.3039 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5482) %, meaning that it created substantial loss on money invested by shareholders. Skye Bioscience,'s management efficiency ratios could be used to measure how well Skye Bioscience, manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 18.54, whereas Return On Tangible Assets are forecasted to decline to (3.31). At present, Skye Bioscience,'s Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 12.2 M, whereas Total Assets are forecasted to decline to about 6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jack Anders | Revolution Medicines | 48 | |
| Cezar MBA | Vaxart Inc | 51 | |
| MSc MBA | Passage Bio | 55 | |
| Path FRCP | Revolution Medicines | 61 | |
| Michelle Corral | Alector | N/A | |
| David Pompliano | Revolution Medicines | N/A | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Mark MD | Passage Bio | 60 | |
| JD Esq | Black Diamond Therapeutics | 59 | |
| Carol Lizak | Jaguar Animal Health | 60 | |
| FACR MD | Cabaletta Bio | 59 | |
| Samik MD | Cabaletta Bio | N/A | |
| Erica Jefferson | Alector | N/A | |
| Simona King | Passage Bio | 52 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| Fang PharmD | Black Diamond Therapeutics | 37 | |
| Dr Stapleton | Vaxart Inc | 53 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Elizabeth Montgomery | Black Diamond Therapeutics | 52 | |
| John Castle | Monte Rosa Therapeutics | 53 | |
Management Performance
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.3 |
Skye Bioscience, Common Leadership Team
Elected by the shareholders, the Skye Bioscience,'s board of directors comprises two types of representatives: Skye Bioscience, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Skye. The board's role is to monitor Skye Bioscience,'s management team and ensure that shareholders' interests are well served. Skye Bioscience,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Skye Bioscience,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, President, Chairman | ||
| Punit BA, President Chairman | ||
| Kaitlyn CPA, Chief Officer | ||
| FACE MD, Chief Officer | ||
| Tu MSc, Chief Officer | ||
| Christopher Twitty, Chief Officer |
Skye Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Skye Bioscience, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 12.57 M | ||||
| Shares Outstanding | 30.34 M | ||||
| Shares Owned By Insiders | 1.89 % | ||||
| Shares Owned By Institutions | 85.41 % | ||||
| Number Of Shares Shorted | 1.59 M | ||||
| Price To Book | 1.05 X | ||||
| EBITDA | (13.55 M) | ||||
| Net Income | (37.64 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.